**Background of HADH Antibody**
HADH (Hydroxyacyl-CoA Dehydrogenase), also known as 3-hydroxyacyl-CoA dehydrogenase, is a mitochondrial enzyme critical in fatty acid β-oxidation. It catalyzes the reversible dehydrogenation of 3-hydroxyacyl-CoA to 3-ketoacyl-CoA, facilitating energy production from fatty acids. Genetic mutations in *HADH* are linked to inherited metabolic disorders, such as HADH deficiency (previously termed SCHAD deficiency), characterized by hypoketotic hypoglycemia, hepatic dysfunction, and neuromuscular complications.
HADH antibodies are essential tools in research and diagnostics, enabling the detection and quantification of HADH protein expression in tissues or cells. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study HADH’s role in metabolic pathways, its tissue-specific distribution, and its association with diseases. In clinical settings, HADH antibodies aid in confirming suspected cases of HADH deficiency through enzymatic activity assays or protein expression analysis.
Recent studies also explore HADH’s involvement in cancer, as altered fatty acid metabolism is a hallmark of tumor progression. Researchers utilize HADH antibodies to investigate its potential as a biomarker or therapeutic target. Overall, HADH antibodies bridge fundamental research and clinical applications, advancing our understanding of metabolic regulation and disease mechanisms.